Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabiola Atzeni

Showing results (61-70 of 438) with videos related to

Pageof 44
Sort By:
Journal of Clinical Medicine|February 25, 2022
Frequency of Renal Function Parameter Abnormalities in Patients with Psoriatic Arthritis and Rheumatoid Arthritis: Real-World Evidence from Clinical PracticeFabiola Atzeni, Pietro Muto, Javier Rodríguez-Carrio, et al.
Clinical and Experimental Rheumatology|May 19, 2026
Fibromyalgia and metabolic syndrome: prevalence, potential shared pathophysiological mechanisms and non-pharmacological treatment strategiesAlessandra Alciati, Francesca Cracò, Alessandra Burgio, et al.
Expert Opinion on Pharmacotherapy|March 22, 2023
Conventional, biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors and varicella zoster virusFabiola Atzeni, Francesco Gozza, Agostino Riva, et al.
Pharmacological Research|April 7, 2021
Behçet disease: From pathogenesis to novel therapeutic optionsJavier Rodríguez-Carrio, Valeria Nucera, Ignazio Francesco Masala, et al.
Clinical and Experimental Rheumatology|September 28, 2010
Successful treatment of leg ulcers in Behçet's disease using adalimumab plus methotrexate after the failure of infliximabFabiola Atzeni, Pietro Leccese, Salvatore D'Angelo, et al.
Autoimmunity Reviews|September 15, 2007
Potential target of infliximab in autoimmune and inflammatory diseasesFabiola Atzeni, Andrea Doria, Mario Carrabba, et al.
Biologics : Targets & Therapy|March 26, 2013
Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritisMaurizio Benucci, Gianantonio Saviola, Mariangela Manfredi, et al.
Expert Review of Clinical Immunology|August 1, 2013
Lung involvement and drug-induced lung disease in patients with rheumatoid arthritisFabiola Atzeni, Luigi Boiardi, Salvatore Sallì, et al.
European Journal of Internal Medicine|March 22, 2023
C-reactive protein level association with future cardiovascular events assessed by different risk scores among rheumatoid arthritis patientsGian Luca Erre, Elena Bartoloni, Ombretta Viapiana, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 20, 2020
Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and RisksSalvatore Crisafulli, Valentina Isgrò, Laura La Corte, et al.
Pageof 44

Showing results (61-70 of 438) with videos related to

Sort By:
Pageof 44
Journal of Clinical Medicine|February 25, 2022
Frequency of Renal Function Parameter Abnormalities in Patients with Psoriatic Arthritis and Rheumatoid Arthritis: Real-World Evidence from Clinical PracticeFabiola Atzeni, Pietro Muto, Javier Rodríguez-Carrio, et al.
Clinical and Experimental Rheumatology|May 19, 2026
Fibromyalgia and metabolic syndrome: prevalence, potential shared pathophysiological mechanisms and non-pharmacological treatment strategiesAlessandra Alciati, Francesca Cracò, Alessandra Burgio, et al.
Expert Opinion on Pharmacotherapy|March 22, 2023
Conventional, biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors and varicella zoster virusFabiola Atzeni, Francesco Gozza, Agostino Riva, et al.
Pharmacological Research|April 7, 2021
Behçet disease: From pathogenesis to novel therapeutic optionsJavier Rodríguez-Carrio, Valeria Nucera, Ignazio Francesco Masala, et al.
Clinical and Experimental Rheumatology|September 28, 2010
Successful treatment of leg ulcers in Behçet's disease using adalimumab plus methotrexate after the failure of infliximabFabiola Atzeni, Pietro Leccese, Salvatore D'Angelo, et al.
Autoimmunity Reviews|September 15, 2007
Potential target of infliximab in autoimmune and inflammatory diseasesFabiola Atzeni, Andrea Doria, Mario Carrabba, et al.
Biologics : Targets & Therapy|March 26, 2013
Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritisMaurizio Benucci, Gianantonio Saviola, Mariangela Manfredi, et al.
Expert Review of Clinical Immunology|August 1, 2013
Lung involvement and drug-induced lung disease in patients with rheumatoid arthritisFabiola Atzeni, Luigi Boiardi, Salvatore Sallì, et al.
European Journal of Internal Medicine|March 22, 2023
C-reactive protein level association with future cardiovascular events assessed by different risk scores among rheumatoid arthritis patientsGian Luca Erre, Elena Bartoloni, Ombretta Viapiana, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 20, 2020
Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and RisksSalvatore Crisafulli, Valentina Isgrò, Laura La Corte, et al.
Pageof 44